Contrasting Iqvia (NYSE:IQV) and Eloxx Pharmaceuticals (NYSE:ELOX)

Eloxx Pharmaceuticals (OTCMKTS:ELOX) and Iqvia (NYSE:IQV) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, dividends, analyst recommendations and valuation.


This table compares Eloxx Pharmaceuticals and Iqvia’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Eloxx Pharmaceuticals N/A N/A N/A
Iqvia 2.35% 15.08% 4.80%

Earnings & Valuation

This table compares Eloxx Pharmaceuticals and Iqvia’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Eloxx Pharmaceuticals N/A N/A N/A N/A N/A
Iqvia $10.41 million 3,048.60 $259.00 million $5.12 31.43

Iqvia has higher revenue and earnings than Eloxx Pharmaceuticals.

Institutional & Insider Ownership

89.7% of Iqvia shares are held by institutional investors. 44.0% of Eloxx Pharmaceuticals shares are held by insiders. Comparatively, 6.0% of Iqvia shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings for Eloxx Pharmaceuticals and Iqvia, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eloxx Pharmaceuticals 0 1 2 0 2.67
Iqvia 0 2 17 2 3.00

Eloxx Pharmaceuticals currently has a consensus price target of $19.33, suggesting a potential upside of 93.92%. Iqvia has a consensus price target of $156.24, suggesting a potential downside of 2.89%. Given Eloxx Pharmaceuticals’ higher possible upside, research analysts clearly believe Eloxx Pharmaceuticals is more favorable than Iqvia.


Iqvia beats Eloxx Pharmaceuticals on 8 of the 10 factors compared between the two stocks.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.

About Iqvia

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order to life science companies, and investment and financial sectors that deal with life science companies; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level to pharmaceutical sales organizations. The Research & Development Solutions segment offers biopharmaceutical development services comprising project management and clinical monitoring, clinical trial support, and strategic planning and design services, as well as clinical trial, genomic, and bioanalytical laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. IQVIA Holdings Inc. serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.

Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with's FREE daily email newsletter.